Patient Power®
Get Email Alerts!
Health Topics
Myeloproliferative Disorders Health Center
Health Center Home Audio Programs Videos Conference Coverage
  • ASH 2012
    • Search by Keyword:
    Search by Health Topic:
    View all Health Topics >
    9/24/12

    The Latest in Myelofibrosis

    As genetic mutations for various cancer types are discovered, researchers have gone to work developing new medicines that inhibit those mutations. Such is the case with the JAK2 mutation now tied to myelofibrosis and scarring in the bone marrow. The first JAK2 inhibitor, Jakafi (ruxolitinib), is now approved in the U.S. and Europe. Dr. Tiziano Barbui, a myelofibrosis expert from Italy, explains how the new medicine can help. 

     

    Get Email Updates:

    Get updated automatically when new content about Myeloproliferative Disorders has been posted.
    Privacy Policy
    Myeloproliferative Disorders

    Experts & Guests

    Tiziano Barbui, M.D. Tiziano Barbui, M.D.
    Professor, Ospedali Riuniti di Bergamo (Italy)
    Tiziano Barbui is Professor of Hematology and Scientific Director of the Research Foundation at Ospedali Riuniti di Bergamo (Italy). From 1981 until 2008 he was head of Department of Hematology at the Ospedali Riuniti di Bergamo. He has served as a chairman on the Subcommittee on Lupus Anticoagulant of the International Society of Thrombosis and Haemostasis, and as President of the... more >

    Transcript

    1. The Latest in Myelofibrosis

    Related Videos

    Dr. Ruben Mesa talks about the latest in MPN research and gives us a glimpse of what the treatment landscape is shaping up to be.

    Watch Now
    Dr. Tiziano Barbui parla su nuovi farmaci che combattono mielofibrosi e di come la scoperta di mutazioni genetiche continuano a modificare il paesaggio trattamento.

    Watch Now
    Dr. Rubén Mesa habla sobre lo último en investigación NMP y nos da una idea de lo que el paisaje tratamiento se perfila a ser.

    Watch Now